Skip to main content
Assets
Amgen logo
AMGN.NASDAQ
Amgen
Health Care · Biotechnology

Biotechnology pioneer discovering, developing, manufacturing, and delivering human therapeutics for serious illnesses.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Amgen.

Historical AI Opinions

Amgen Inc. (AMGN.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+56.6%

Includes 1.73% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.171.35259.74348.13436.53524.92Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$358+4.0%Not Generated this time
$372+8.0%Not Generated this time
$389+12.8%Not Generated this time
$405+17.7%Not Generated this time
$422+22.5%Not Generated this time
$439+27.3%Not Generated this time
$454+31.7%Not Generated this time
$468+35.9%Not Generated this time
$482+39.9%Not Generated this time
$495+43.8%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The most reasonable thesis projects Amgen effectively navigating its transition period. MariTide will likely succeed in clinical trials, securing approval by late 2027, though it may share the market rather than dominate it, serving as a robust growth pillar alongside a stabilized Horizon portfolio. The loss of exclusivity for Prolia and Xgeva will create revenue headwinds in 2026-2027, but Amgen's proven ability to manage lifecycle extensions and its own aggressive biosimilar revenue growth (e.g., Amjevita, Wezlana) will mitigate the impact. The company will maintain its shareholder-friendly capital allocation, growing the dividend while deleveraging. The stock offers a balanced risk-reward profile, steadily compounding as the obesity pipeline de-risks.

2. Scenarios & Signals

2.1. Bull Case

The bull case hinges on the transformational success of MariTide (AMG 133) in the obesity and metabolic disease market. In this scenario, Phase 3 'MARITIME' trials demonstrate best-in-class efficacy with a durable weight loss profile and superior monthly or quarterly dosing convenience compared to daily/weekly competitors. This propels Amgen to capture a significant double-digit share of the projected $100B+ obesity market by 2030. Simultaneously, the integration of Horizon Therapeutics exceeds synergy targets, with Tepezza returning to high-growth trajectory globally. Amgen's own biosimilar portfolio aggressively captures share from competitors like Stelara, offsetting the Prolia/Xgeva patent cliff. The market re-rates AMGN from a value pharma to a high-growth biotech multiple, driving the stock significantly higher.

2.2. Bear Case

The bear case envisions a failure or significant safety signal in the MariTide Phase 3 program, shattering the premium currently baked into the stock price. Without this growth engine, investor focus shifts aggressively to the 'patent cliff' facing Prolia and Xgeva, where biosimilar erosion accelerates faster than anticipated starting in 2026, severely impacting high-margin revenue. The Horizon Therapeutics acquisition proves burdensome, with Tepezza sales plateauing due to competitive thyroid eye disease therapies. Burdened by debt from the acquisition and lacking a near-term blockbuster replacement, Amgen faces margin compression and multiple contraction, reverting to a low-growth yield trap valuation.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 1,819Thinking Tokens: 1,845Response Tokens: 7,209Total Tokens: 10,873
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.